Home › Acute myeloïde leukemie › New Jersey › Newark
Acute myeloïde leukemie klinische studies in Newark, NJ
12 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Newark (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mijl verwijderd
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Morristown Medical Center, Morristown · 17 mijl verwijderd
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mijl verwijderd
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mijl verwijderd
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mijl verwijderd
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mijl verwijderd
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruterenFase 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · 17 mijl verwijderd
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RekruterenFase 1/2
- Atlantic Health, Morristown · 17 mijl verwijderd
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- Morristown Medical Center, Morristown · 17 mijl verwijderd
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruterenFase 3
- Morristown Medical Center, Morristown · 17 mijl verwijderd
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RekruterenFase 2/3
- Atlantic Health, Morristown · 17 mijl verwijderd
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- Atlantic Health, Morristown · 17 mijl verwijderd
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Andere studies in Newark
- Borstkanker18 studies
- Ruggenmergletsel13 studies
- Niet-kleincellige longkanker13 studies
- Hartfalen10 studies
- Metastatische kanker10 studies
- Cardiovasculaire ziekte9 studies
- Aldermeesklierkanker9 studies
- Melanoom8 studies
- Kanker (alle vormen)7 studies
- Longkanker7 studies
- Ziekte van Crohn7 studies
- Stenose van de aortaklep6 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.